Evidence mapPaperPMID 39209472Full record

ReviewThe European respiratory journal2024

Risk stratification and treatment goals in pulmonary arterial hypertension.

Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J Rubin, Marius M Hoeper

Registry-linked trialAbstract readReview
In one paragraph

Review in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07667673 (Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07667673 recruitingnot on this mapstarted 2026, after this paper: background citation

Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study

TypeobservationalSponsorIstanbul University - CerrahpasaRan2026 to 2027Enrolled50ConditionsPulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Update on pulmonary hypertension.Respiratory research · 2026
    Review
  20. Advancing the diagnosis of pulmonary arterial hypertension-a Brazilian perspective aligned with global standards.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Fabio DardiCardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0001-9611-6021
Athénaïs BouclyUniversité Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0001-6246-5557
Raymond BenzaIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID https://orcid.org/0000-0001-9627-6236
Robert FrantzDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0003-4128-3978
Valentina MercurioDepartment of Translational Medical Sciences, Federico II University, Naples, Italy.
Horst OlschewskiDiv. Pulmonology, Department Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0002-2834-7466
Göran RådegranDepartment of Clinical Sciences Lund, Cardiology, Lund University and The Haemodynamic Lab, VO Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden.ORCID https://orcid.org/0000-0003-4919-2771
Lewis J RubinUniversity of California San Diego School of Medicine, San Diego, CA, USA ljr@lewisrubinmd.com.
Marius M HoeperDepartment of Respiratory Medicine and Infectious Disease, Hannover Medical School and the German Center for Lung Research (DZL), Hannover, Germany.ORCID https://orcid.org/0000-0001-9086-2293

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.

Indexed as

Pulmonary Arterial HypertensionBiomarkersHemodynamicsHumansHypertension, PulmonaryNatriuretic PeptidesPrognosisRisk AssessmentSeverity of Illness IndexWalk TestBiomarkersNatriuretic Peptides

Identifiers

PMID39209472
PMCPMC11525341

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.